[Animal experimental examination of a phase III study on the effect of the combination therapy of bruneomycin, cytostasan and prednisone].
The effectivity of a combined application of Bruneomycin, Cytostasane and Prednisone has been tested in five qualitatively different experimental animal test models. The selected dose levels and the treatment schedule were based on an instruction given in a phase III-study. No effectivity was demonstrable in any of the tumor systems selected neither with the single components, nor with their combination, though the toxicity clearly revealed a dose dependence.
D000818:Animals; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy*; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013308:Streptonigrin / Q000627:therapeutic use*
D009588:Nitrogen Mustard Compounds; D013308:Streptonigrin; D000069461:Bendamustine Hydrochloride; D011241:Prednisone
Tierexperimentelle Uberprüfung der Phase-III-Studie zur Wirkung einer Kombinationstherapie von Bruneomycin, Cytostasan und Prednison.